Sotagliflozin
- Generic Name
- Sotagliflozin
- Brand Names
- Inpefa
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25ClO5S
- CAS Number
- 1018899-04-1
- Unique Ingredient Identifier
- 6B4ZBS263Y
- Background
Sotagliflozin is a dual inhibitor of SGLT1 and SGLT2, the first of its kind, which is approved for use in the EU, in combination with insulin, to improve glycemic control in patients with type 1 diabetes mellitus (T1DM) and a BMI ≥27 kg/m. Its potency in inhibiting SGLT2 is similar to that of other SGLT2 inhibitors, such as canagliflozin and dapagliflozin, b...
- Indication
用于体重指数≥27kg/m2且接受最佳胰岛素疗法仍无法达到足够血糖控制的1型糖尿病（T1D）成人患者。
- Associated Conditions
- Cardiovascular Mortality, Heart Failure
- Associated Therapies
- -
A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone
- Conditions
- Interventions
- First Posted Date
- 2015-08-21
- Last Posted Date
- 2020-02-12
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 1405
- Registration Number
- NCT02531035
- Locations
- 🇬🇧
Lexicon Investigational Site, Northampton, United Kingdom
Oral Contraceptive DDI Study
- Conditions
- Interventions
- First Posted Date
- 2015-07-10
- Last Posted Date
- 2016-03-02
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 30
- Registration Number
- NCT02494609
- Locations
- 🇺🇸
Lexicon Investigational Site, Dallas, Texas, United States
PK Study of Sotagliflozin in Subjects With Hepatic Impairment
- First Posted Date
- 2015-06-15
- Last Posted Date
- 2016-11-17
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 32
- Registration Number
- NCT02471274
- Locations
- 🇺🇸
Lexicon Investigational Site, Minneapolis, Minnesota, United States
Dose-ranging Study in Patients With Type 1 Diabetes Mellitus
- First Posted Date
- 2015-06-02
- Last Posted Date
- 2020-02-12
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 141
- Registration Number
- NCT02459899
- Locations
- 🇺🇸
Lexicon Investigational Site, Manassas, Virginia, United States
Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy
- First Posted Date
- 2015-04-20
- Last Posted Date
- 2020-02-12
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 782
- Registration Number
- NCT02421510
- Locations
- 🇬🇧
Lexicon Investigational Site, Sheffield, United Kingdom
Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy
- First Posted Date
- 2015-03-10
- Last Posted Date
- 2020-02-12
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 793
- Registration Number
- NCT02384941
- Locations
- 🇨🇦
Lexicon Investigational Site, St. Laurent, Quebec, Canada
Efficacy and Safety of Sotagliflozin in Young Adult Patients With Type 1 Diabetes Mellitus and Elevated Hemoglobin A1C
- First Posted Date
- 2015-03-10
- Last Posted Date
- 2020-02-12
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 87
- Registration Number
- NCT02383940
- Locations
- 🇺🇸
Lexicon Investigational Site, Salt Lake City, Utah, United States
Safety and Efficacy of Sotagliflozin (LX4211) in Patients With Inadequately Controlled Type 1 Diabetes Mellitus
- First Posted Date
- 2012-12-05
- Last Posted Date
- 2020-02-12
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 36
- Registration Number
- NCT01742208
- Locations
- 🇺🇸
Lexicon Investigational Site, Dallas, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.